.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Paradigms in Insulin Use for Type 2 Diabetes

Jennifer Brigitte Green, MD, discusses the management of type 2 diabetes for patients not currently controlled on oral antidiabetic medications.

EP. 1: Treatment Approach for Patients With Type 2 Diabetes

December 22nd 2021

Jennifer Brigitte Green, MD, reviews her treatment approach for managing patients with type 2 diabetes and shares insight on how to identify patients that are uncontrolled with oral antidiabetic agents.

EP. 2: Type 2 Diabetes: Considerations for Achieving Targeted Glycemic Control

January 20th 2022

Dr Jennifer Brigitte Green addresses clinical considerations for patients with type 2 diabetes who are not responding to their oral antidiabetic agents and discusses her strategy for insufficient target glycemic control with insulin regimens.

EP. 3: Clinical Inertia in Treatment of Type 2 Diabetes

January 27th 2022

Jennifer Brigitte Green, MD, discusses the reasoning behind clinical inertia in treating patients with type 2 diabetes and comments on achieving and maintaining glycemic control over an extended period.

EP. 4: Fixed-Ratio Combinations for Type 2 Diabetes

January 27th 2022

Dr Jennifer Brigitte Green considers the patient selection for fixed-ratio combinations of basal insulin and GLP-1 receptor agonists among patients with type 2 diabetes and provides insight around Medicare patient access to insulin and injectable medications.

EP. 5: Managing Type 2 Diabetes With Fixed-Ratio Combinations

February 22nd 2022

Rodolfo J. Galindo, MD, provides insight on the benefit of fixed-ratio combinations of basal insulin and GLP1 agonists for the optimal management of type 2 diabetes.

EP. 6: LixiLan-O and DUAL Studies in Type 2 Diabetes

February 22nd 2022

A key opinion leader reviews clinical data for newly approved injectable medications, iGlarLixi and iDegLira, for the management of type 2 diabetes as seen in the LixiLan-O and DUAL studies.

EP. 7: Advantages of Using Fixed-Ratio Combinations in Type 2 Diabetes

March 1st 2022

Rodolfo J. Galindo, MD, comments on the benefits of fixed-ratio combination therapies for the management of type 2 diabetes compared with premixed insulin.

EP. 8: AMCP Nexus 2021 Updates on iGlarLixi in Type 2 Diabetes

March 1st 2022

An expert in endocrinology reviews updates from the AMCP Nexus 2021 conference on treatment persistence and adherence with iGlarLixi versus free-dose combinations of basal insulin and GLP-1 receptor agonists, and shares insight on future directions for disease management.